Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $3.53 and traded as low as $2.70. Sensus Healthcare shares last traded at $2.73, with a volume of 27,028 shares changing hands.
Analyst Ratings Changes
SRTS has been the subject of several research reports. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Alliance Global Partners initiated coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They set a “buy” rating and a $7.50 price target for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Finally, Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sensus Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $6.88.
View Our Latest Stock Analysis on Sensus Healthcare
Sensus Healthcare Stock Performance
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Opes Wealth Management LLC acquired a new stake in shares of Sensus Healthcare in the third quarter valued at about $50,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the fourth quarter worth approximately $77,000. Jane Street Group LLC bought a new stake in Sensus Healthcare in the fourth quarter valued at approximately $79,000. Mindset Wealth Management LLC boosted its holdings in Sensus Healthcare by 28.1% in the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare during the 4th quarter valued at approximately $219,000. 25.30% of the stock is owned by institutional investors and hedge funds.
About Sensus Healthcare
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Featured Articles
- Five stocks we like better than Sensus Healthcare
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
